FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Jemperli (dostarlimab-gxly), an immunotherapy, for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This approval offers a new treatment approach that may allow some patients to avoid chemotherapy, radiation, and surgery, which can have lasting impacts on daily life.